Interleukin-1beta converting enzyme like cysteine protease
AssigneeAmgen Inc.
InventorsShao-Chieh Juan, Frederick A. Fletcher, Scott D. Patterson
Life of this patent
Estimating the term…
Abstract
A new member of a family of ICE-like cysteine proteases has been identified. The protease family is termed LICE (Like ICE) and the family member described herein is LICE3. LICE3 polypeptides, nucleic acids encoding LICE3 and vectors and host cells for the expression LICE3 are disclosed. Also disclosed are methods for identifying LICE3 agonists and antagonists, and methods for treatment of disorders characterized by altered apoptosis.
Claims27
An isolated nucleic acid encoding a polypeptide comprising at least one of the biological activities of LICE3 wherein the nucleic acid is selected from the group consisting of:
- a) the nucleic acid shown in FIG. 1 (SEQ ID NO:
- ______);
- b) nucleic acids which hybridize to the polypeptide coding regions of the nucleic acids shown in FIG. 1 (SEQ ID NO:
- ______) and remain hybridized to the nucleic acids under high stringency conditions;
- and
- c) nucleic acids which are degenerate to the nucleic acids of (a) or (b).
A nucleic acid encoding a polypeptide having the amino acid sequence of SEQ. ID. NO.______.
A polypeptide having the amino acid sequence as shown in FIG. 1 (SEQ ID NO:______) or a derivative thereof having at least about 60% homology to the amino acid sequence as shown in FIG. 1 (SEQ ID NO:
- ______) wherein the polypeptide has at least one of the biological activities of LICE3.
An antibody or fragment thereof which specifically binds LICE3.
A method to assess the ability of a candidate compound to bind LICE3 comprising:
- incubating LICE3 with the candidate compound under conditions that allow binding;
- and
- measuring the bound compound.
A method of regulating expression of LICE3 in an animal comprising administering to the animal a nucleic acid complementary to the nucleic acids as shown in FIG. 1 (SEQ ID NO:______).
A pharmaceutical composition comprising a therapeutically effective amount of LICE3 in a pharmaceutically acceptable carrier, adjuvant, solubilizer, stabilizer and/or anti-oxidant.
A method of treating a disorder characterized by increased apoptosis comprising administering a therapeutically effective amount of a LICE3 antagonist.
A method of treating a disorder characterized by increased cell proliferation comprising administering a therapeutically effective amount of LICE3.
Dependencies are inferred from the claim text.